Views
4 years ago

72 - A Sayús - Febrero 2012

  • Text
  • Sayus
  • Bipolar
  • Cognitivos
  • Valpromida
  • Sodio
  • Magnesio
  • Sodio
  • Valproico
  • Psico
  • Receptores
  • Trastornos
  • Alteraciones
  • Valproic
  • Bipolar
  • Hiperamonemia
  • Pacientes
  • Valproico
Trastornos neurocognitivos en la hiperamonemia inducida por ácido valproico

Dr. Alejandro

Dr. Alejandro Sayús hacia cuadros más severos, por lo menos en lo reportado en la literatura científica. Cuestión que no ocurre con las encefalopatías hiperamonémicas debidas a enfermedades hepáticas y otras, las que pueden tener un vaivén desde los síntomas leves a los más severos y viceversa. Los estudios neuropsicológicos pueden permitir diferenciar un deterioro cognitivo propio de la enfermedad bipolar en eutimia de aquel que es producto de la hiperamonemia. El primero tiene un patrón de características fronto-subcorticales, y el segundo más preponderantemente corticales. Cabe aclarar que las evaluaciones neurocognitivas deben ser hechas por profesionales altamente capacitados tratando de realizar una evaluación global. Aunque no es imprescindible, puede ser de utilidad la realización de esas pruebas al comienzo del tratamiento de un paciente bipolar para tener una referencia de comparación. Referencias bibliográficas 1. Wormer Eberhard J. Depresión y Manía. Vivir con emociones extremas. Pág. 86-87. Ediciones Robinbook 2004 Barcelona. España. 2. López Muñoz F. – Álamo C. Historia de la Psicofarmacología. TomoII Pág. 772-776 Editorial Panamericana 2007 Madrid. España. 3. Kralj C. Bertera H. Estabilizadores del ánimo. Parte II. Antiepilépticos de utilidad en el tratamiento del Trastorno bipolar. Tratado de psicofarmacología y neurociencia: trastornos del estado de ánimo y bipolaridad. Trastornos psiquiátricos y cognitivos en la epilepsia. Director Zieher L. M. 1ª. Ed. Buenos Aires:Sciens, 2011 pag.57-102. 4. Grayson D, Kundakovic M, Sharma R. Is there a furure for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Molecular Pharmacology 2010. 72(2): 126-135. 5. Stefan M, Bavli S. Recurrent Stupor Associated with Chronic Valproic Acid Therapy and Hyperammonenia. Hospital Physician March/April 2009. 47: 17-20. 6. Murphy J V, Marquardt K. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch. Neurol. 1982; 39:591-2. 7. Raja M, Azzoni A: Valproate-induced hyperammonaemia. J Clin Psychopharmacol 2002; 22:631–633. 8. Carr B, Shrewsbury K. Hyperammonemia Due to Valproic Acid in de Psychiatric Setting. Am J Psychiatry 164; 7: 10. 9. Riva R, Albani F, Gobbi G, Santucci M, Baruzzi A. Carnitine disposition before and during valproate therapy in patients with epilepsy. Epilepsia. 1993 Jan-Feb;34(1):184-7. 10. Hye Y K. Renal Handling of Ammonium and Acid Base Regulation Electrolytes & Blood Pressure 7:9-13, 2009 9. 11. Ferrier B, Martin M,. Baverel G. Valproate- Induced Stimulation of Renal Ammonia Production and Excretion in the Rat J. Clin. Chem. Clin. Biochem. Vol. 26,1988, pp. 65-67. 12. Brusilow S W, Koehler R C, Traytsman R J, Cooper A J L. Astrocyte Glutamine Syntethase: Importance in Hyperammonemic Syndromes and Potencial Target for Therapy. Neurotherapeutics 2010. Vol 7 Nº 4 October: 452-470. 13. Butterworth R F. Glutamate transporters in hyperammonemia. Neurochemistry International 2002. 41: 8185. 14. Bélanger, M., Desjardins, P., Chatauret, N., Butterworth, R.F. Loss of expression of glial fibrillary acidic protein in acute hyperammonemia.2002 Neurochem. Int. 41: 155–160. 15. Takanashi J, Barkovicha J, Cheng S F, Kostiner D, Baker J C, Packman S. Brain MR Imaging in Acute Hyperammonemic Encephalopathy Arising from Late-Onset Ornithine Transcarbamylase Deficiency. AJNR 2003 24:390-393. 16. Skowrońska M, Albrecht J. Alterations of Blood Brain Barrier Function in Hyperammonemia: An Overview. Neurotox Res. 2012 February; 21(2): 236–244. 17. Clemmesen, J.O., Larsen, F.S., Kondrup, J., Hansen, B.A., Ott, P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. 1999 Hepatology 29, 648–653. 18. Bélanger M, Ahboucha S, Desjardins P, Butterworth R S. Upregulation of peripheraltype(mitochondrial) benzodiazepine receptors in hyperammonemic syndromes: consequences for excitability. Advances in Molecular and Cell Biology 2004. Vol 31:pages 983-997. 19. Zwingmann, C., Desjardins, P., Michalak, A., Hazell, A.S., Chatauret, N., Butterworth, R.F., 2002. Reduced expression of the astrocytic glycine transporter Glyt-1 in acute liver failure. Metab. Brain Dis. 17, 263–274. 20. Margulies, J.E., Thompson, R.C., Demetriou, A.A., 1999. Aquaporin-4 water channel is upregulated in the brain in fulminant hepatic failure. Hepatology 30, 395A. 21. Knecht, K., Michalak, A., Rose, C., Rothstein, J.D., Butterworth, R.F., 1997. Decreased glutamate transporter (GLT-1) expression in frontal cortex of rats with acute liver failure. Neurosci. Lett. 229, 201–203. 22. Zwingmann, C., Desjardins, P., Michalak, A., Hazell, A.S., Chatauret, N., Butterworth, R.F., 2002. Reduced expression of the astrocytic glycine transporter Glyt-1 in acute liver failure. Metab. Brain Dis. 17, 263–274. 23. Atterbury C E, Maddrey W C, Conn H O. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial.Am J Dig Dis. 1978; 23(5):398-406. 24. Correa E, Alonso Ortega G, Risco L, Ivanovic Zuvic F. Trial Making Test in bipolar patients with hyperammonemia secondary to valproic acid. Trastor. ánimo 2006;Vol 2, Nº 2:81-82. 25- Herrera F, Correa E, Velásquez V. Neurocognition in valproic acid induced hyperammonemia: L-carnitina treatment effect. Trastor. ánimo 2006; Vol 2 Nº 2:113-120. 26. Hamberger A, Nyström B. Extra and intracellular amino acids in the hippocampus during development of hepatic encephalopathy. Neuro¬chem Res 1984;9:1181-92. 27. McArdle P, Penning DH, Dexter F, Reynolds JD. Flumazenil does not affect the increase in rat hippocampal extracellular glutamate con¬centration produced during thioacetamide-induced hepatic encephalo¬pathy. Metab Brain Dis 1996;11:329- 42. 28. Halgren E, Squires N, Wilson C, Rohrbaugh J, Bab T, Crandall P. Endogenous potentials in the human hippocampal formation and amyg¬dala by infrequent events. Science 1980;210:803-5. 29. Mccarthy G, Wood CC, Williamson PD, Spencer DD. Task-de¬pendent field potentials in human hippocampal formation. J Neurosci 1989;9:4253. 30. Bragagnolo M A, Teodoro V, Mendonça Lucchesi L, Ferreira Santos R, de Castro Amaral Feldner A C, Campanha da Rocha Ribeiro T, Tufik S, Kondo M. Correlation between ammonia and event-related evoked potentials (P300) in cirrhotic patients. Rev Neurocienc 2009; 17 (2) : 122-27. 31. Dupont R M, Jernigan T L, Heindel W, Butters N, ShaferK , Wilson T, Hesselink J,Gillin J C. Magnetic Resonance Imaging and mood disorders, Arch Gen Psychiatry 1995b; 52 (9):747-755. 32. Videbech P. MRI findings in patients with affective disorder: a meta-analysis. Acta Psychiatr Scand 1997 Sep; 96(3):157-68. 33. Glahn D C, Bearden C E, Barguil M, Barret J, Reichenberg A, Bowden C L, Soares J C, Velligan D I. The neurocognitive signature of psychotic bipolar disorder. Biol Psychiatry 2007 Oct 15;62 (8): 910-16. 34. Ferrier I N, Stanton B R, Kelly T P, Scott J. Neuropsychological function in eutimic patients with bipolar disorder. B J Psych. 1999. 175:245-251. 35. Schneider J J, Candiago R M, Rosa A R, Ceresér K M, Kapczinski F. Cognitive impairment in a brazilian sample of patients with bipolar disorder. Rev. Bras. Psiquiatr. Sept. 2008. Vol. 30 nº 3. Sao Paulo. 36. Calabrese J R, Markovitz P J, Kimmel S E, Wagner S C. Spectrum of efficacy of valproate in 78 rapid cycling bipolar patients. J Clin Psychopharmacol. 1992 12(1Suppl):53S-56S. 37. Kavoussi R J, Coccaro E F, Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J.Clin. Psychiatry 1998. 59(12): 676-80. 38. Bogan A M, Brown E S, Suppes T. Efficacy of divalproex therapy for schizoaffective disorder. J. Clin. Psychopharmacol. 2000. 20(5): 520-2. 26 // EDITORIAL SCIENS

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015